课题基金 / 基金详情

Regulation of Lung Barrier Function by Endothelial Cell (EC) MLCK

Regulation of Lung Barrier Function by Endothelial Cell (EC) MLCK
内皮细胞 (EC) MLCK 对肺屏障功能的调节
批准号:
8214989
负责人:
Joe G. N. Garcia
金额:
$30.06万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-02-01 至 2013-01-31

项目摘要

项目成果

Joe G. N. Garcia的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project #1 studies have demonstrated that the gene encoding the multi-functional cytoskeletal protein, myosin light chain kinase (MLCK), contains coding polymorphisms which are highly associated with susceptibility to acute lung injury (ALI). The non-muscle isoform, nmMLCK, is a critical cytoskeletal effector which regulates the participation of the EC actin cytoskeleton in vascular barrier disruption, in barrier restoration, in lung inflammatory cell trafficking and in vascular responses to mechanical stretch. Following edemagenic agents, MLCK phosphorylates MLCs on Ser19 and Thr18, producing barrier-disrupting cytoplasmic stress fibers, spatially-localized actomyosin contraction and paracelular gaps. In contrast, EC barrier-protective agonists induce the rapid translocation of MLCK to lamellipodial membrane protrusions (to close paracellular gaps and restore barrier integrity) and to cortical actin networks (to enhance linkage to junctional complexes and increase barrier properties). The mechanism by which the full length nmMLCKI (and its five alternatively spliced variants) is targeted to specific cellular sites is entirely unknown. Furthermore, the influence of ALIassociated nmMLCK coding SNPs (Pro21His, Pro147Ser, Val261Ala) on MLCK structure/function are similarly unknown. We hypothesize that site-specific nmMLCK regulation involves post-translational modifications (PTMs) and results in variant- and SNP-specific MLCK activities. Specific Aim (SA) #1 will conduct studies to characterize nmMLCK (nmMLCKI, nmMLCK splice variants, MLCK-coding SNPs) utilizing kinase and actin polymerization assays, GFP/YFP-MLCK fusion proteins and cytoskeletal binding assays. SA #2 will examine the influence of kinase-mediated PTMs (Src, Abl, ERK and PKA) on site-specific MLCK responses (nmMLCKI, nmMLCK-variants, nmMLCK-SNPs) utilizing mass spectroscopy, phosphopeptide mapping, GFP-MLCK fusion proteins, and binding partner assays. SA #3 will examine MLCK regulation of actin polymeriza-tion and focal adhesion remodeling in EC lamellipodia (critical to paracellular gap closure) using GFP-MLCK- and paxillin fusion proteins coupled to atomic force microscopy. SA #4 will utilize available and novel genetically-engineered mice to further define the in vivo role of nmMLCK splice variants (+/- SNPs) in lung inflammatory injury. These translational studies integrate across our entire PPG and lead to mechanistic insights into EC barrier regulation and the development of novel edema-reducing therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
  • 批准号:
    10723260
  • 项目类别:
  • 资助金额:
    $80.9万
  • 财政年份:
    2022
  • 负责人:
    Joe G. N. Garcia
  • 依托单位:
Role of Endothelial eNAMPT Secretion and TLR4 Signaling in the ARDS Vascular Endotype
  • 批准号:
    10440855
  • 项目类别:
  • 资助金额:
    $23.27万
  • 财政年份:
    2022
  • 负责人:
    Joe G. N. Garcia
  • 依托单位:
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
  • 批准号:
    10489982
  • 项目类别:
  • 资助金额:
    $25.96万
  • 财政年份:
    2022
  • 负责人:
    Joe G. N. Garcia
  • 依托单位:
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
  • 批准号:
    10771493
  • 项目类别:
  • 资助金额:
    $97.52万
  • 财政年份:
    2022
  • 负责人:
    Joe G. N. Garcia
  • 依托单位:
海外基金